This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
National Vision (EYE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Earnings Preview: National Vision (EYE) Q3 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to Walgreens Boots (WBA) for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.
Here's Why You Should Hold on to Hill-Rom (HRC) for Now
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Walgreens (WBA) to Make Additional Investment in VillageMD
by Zacks Equity Research
Walgreens (WBA) announced a $5.2-billion investment in VillageMD to bolster its strategic position in delivering value-based primary care.
National Vision (EYE) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
4 Stocks to Keep a Watch on Amid Growing Optical Care Demand
by Riya Anand
Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Company News for Aug 13, 2021
by Zacks Equity Research
Companies In The News Are: CSIQ, DDS, EYE, AZEK
National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.
National Vision (EYE) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 108.70% and 11.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.
National Vision (EYE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes
by Zacks Equity Research
National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.
OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology
by Zacks Equity Research
OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.
Inogen (INGN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.
QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance
by Zacks Equity Research
According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.
NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes
by Zacks Equity Research
We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
Medtronic (MDT) Reports Economic Findings on PRODIGY Data
by Zacks Equity Research
Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.
BD's (BDX) Digital Marketplace Set to Improve User Experience
by Zacks Equity Research
BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.